Ronald Dahl
- Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) useBy Ronald Dahl, Charles Fogarty, David Lawrence, Cheryl Lassen and Benjamin KramerRonald Dahl1Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkCharles Fogarty2Medical Research, Spartanburg Medical Research, Spartanburg, United StatesDavid Lawrence3Novartis Horsham Research Centre, Novartis, Horsham, United KingdomCheryl Lassen3Novartis Horsham Research Centre, Novartis, Horsham, United KingdomBenjamin Kramer4Respiratory Development, Novartis Pharmaceuticals, Hanover, United States
- Smoking prevalence and willingness to quit in newly screened Danish patients diagnosed with airway obstructionBy Jens Dollerup, Peter Bo Poulsen, Charlotte Suppli Ulrik, Anders Løkke, Jens Holt, Jørn Løkke Jensen, Klaus Kaa Andersen and Ronald DahlJens Dollerup1Medical and Access, Pfizer, Ballerup, DenmarkPeter Bo Poulsen1Medical and Access, Pfizer, Ballerup, DenmarkCharlotte Suppli Ulrik2Card. & Pulm. Department, Hvidovre Hospital, Copenhagen, DenmarkAnders Løkke3Pulm Department, Aarhus University Hospital, Aarhus, DenmarkJens Holt4Boehringer Ingelheim, Med. and Acc., Copenhagen, DenmarkJørn Løkke Jensen4Boehringer Ingelheim, Med. and Acc., Copenhagen, DenmarkKlaus Kaa Andersen5Inst of Mat. & Statistics, DTU of Denmark, Kgs. Lyngby, DenmarkRonald Dahl3Pulm Department, Aarhus University Hospital, Aarhus, Denmark
- Early diagnosis of COPD in a high-risk population using spirometric screening in general practiceBy Charlotte Suppli Ulrik, Anders Løkke, Ronald Dahl, Liane Plauborg, Jens Dollerup, Luise Cederkvist Kristiansen, Patrick Hagge Cording and Christian DehlendorffCharlotte Suppli Ulrik1Respiratory Section, Internal Medicine Unit, Hvidovre University Hospital, Hvidovre, DenmarkAnders Løkke2Respiratory Medicine, Århus University Hospital, Århus, DenmarkRonald Dahl2Respiratory Medicine, Århus University Hospital, Århus, DenmarkLiane Plauborg3R&D, Boehringer Ingelheim Denmark, Copenhagen, DenmarkJens Dollerup4R&D, Pfizer Aps Denmark, Ballerup, DenmarkLuise Cederkvist Kristiansen5DTU Informatics, Technical University of Denmark, Lyngby, DenmarkPatrick Hagge Cording5DTU Informatics, Technical University of Denmark, Lyngby, DenmarkChristian Dehlendorff5DTU Informatics, Technical University of Denmark, Lyngby, Denmark
- COPD patients coping with breathlessness during daily living – A multi-modal grounded theoryBy Lene Bastrup Jørgensen, Ronald Dahl, Preben Ulrich Pedersen and Kirsten Elisabeth LomborgLene Bastrup Jørgensen1Department of Nursing Science, School of Publich Health, Aarhus University, Aarhus, DenmarkRonald Dahl2The Department of Pulmonary Medicine, Aarhus University Hospital, Aarhus, DenmarkPreben Ulrich Pedersen1Department of Nursing Science, School of Publich Health, Aarhus University, Aarhus, DenmarkKirsten Elisabeth Lomborg1Department of Nursing Science, School of Publich Health, Aarhus University, Aarhus, Denmark
- QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: The ENLIGHTEN studyBy Ronald Dahl, Kenneth Chapman, Michael Rudolf, Rajendra Mehta, Pearl Kho, Vijay Alagappan, Indrias Berhane, Hungta Chen and Donald BanerjiRonald Dahl1Dept of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkKenneth Chapman2Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, CanadaMichael Rudolf3Dept of Respiratory Medicine, Ealing Hospital NHS Trust and Imperial College, London, United KingdomRajendra Mehta4Allergy and Asthma Care, Allergy and Asthma Care and Research Centre, Indore, IndiaPearl Kho5Novartis Horsham Research Centre, Novartis, Horsham, United KingdomVijay Alagappan6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United StatesIndrias Berhane6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United StatesHungta Chen6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United StatesDonald Banerji6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United States
- Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelinesBy Huib Kerstjens, Ronald Dahl, Ekkehard Beck, Mark Vandewalker, Michael Engel, Ralf Sigmund, Wolfgang Seibold, Petra Moroni-Zentgraf and Eric BatemanHuib Kerstjens1Department of Pulmonary Medicine and Tuberculosis, University Medical Center, Groningen, NetherlandsRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus C, DenmarkEkkehard Beck3Medical Department, IFG - Institut für Gesundheitsförderung GmbH, Rüdersdorf Brandenburg, GermanyMark Vandewalker4Clinical Trials, Clinical Research of the Ozarks, Columbia, MO, United StatesMichael Engel5TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyRalf Sigmund6Biostatistics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyWolfgang Seibold7Clinical Research, Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyPetra Moroni-Zentgraf8TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyEric Bateman9Department of Medicine, University of Cape Town, South Africa
- Once-daily QVA149 has a good safety profile in patients with COPDBy Tobias Welte, Claus Vogelmeier, Ronald Dahl, Kenneth R. Chapman, Michael Rudolf, Rajendra Mehta, Peter D'Andrea, Hungta Chen and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hanover, GermanyClaus Vogelmeier2Department of Respiratory Medicine, Universitätsklinikum Gießen Und Marburg, Marburg, GermanyRonald Dahl3Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkKenneth R. Chapman4Asthma and Airway Center, University of Toronto, Toronto, CanadaMichael Rudolf5Department of Respiratory Medicine, Ealing Hospital, Middlesex, United KingdomRajendra Mehta6Allergy and Asthma Care, Allergy & Asthma Care and Research Centre, Indore, IndiaPeter D'Andrea7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Vitamin D, magnesium and calcium do not correlate with COPD: A cross-sectional studyBy Sarah Hashim Ali Hussein, Lars Peter Nielsen, Mette Konow Bogebjerg Dolberg and Ronald DahlSarah Hashim Ali Hussein1Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkLars Peter Nielsen2Department of Clinical Phamacology, Aarhus University Hospital, Aarhus, DenmarkMette Konow Bogebjerg Dolberg1Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkRonald Dahl3Institute for Clinical Medicine, Aarhus University, Aarhus, Denmark
- Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON studyBy Ronald Dahl, Dalal Jadayel, Vijay Alagappan, Hungta Chen and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkDalal Jadayel2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 improves symptom scores in patients with COPDBy Tobias Welte, Ronald Dahl, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hannover, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Arterial blood gas levels in asthma: A systematic literature reviewBy Troels Johansen, Niels Ejskjær, Peter Johansen, Preben Kidmose and Ronald DahlTroels Johansen1Department of Pulmonary Diseases, Aarhus University Hospital, Aarhus C, DenmarkNiels Ejskjær2Department of Endocrinology, Aarhus University Hospital, Aarhus C, DenmarkPeter Johansen3Aarhus School of Engineering, Aarhus University, Aarhus C, DenmarkPreben Kidmose3Aarhus School of Engineering, Aarhus University, Aarhus C, DenmarkRonald Dahl4Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
- QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPDBy Ronald Dahl, Nicola Gallagher, Yulia Green, Hannah Bryant, Hungta Chen, Peter D'Andrea, Vijay Alagappan and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHannah Bryant2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON studyBy Ronald Dahl, Dalal Jadayel, Vijay Alagappan, Hungta Chen and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkDalal Jadayel2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomesBy Claus Vogelmeier, Ronald Dahl, Anthony D'Urzo, Hungta Chen, Yulia Green and Donald BanerjiClaus Vogelmeier1Department of Respiratory Medicine, Universitätsklinikum Gießen Und Marburg, Marburg, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkAnthony D'Urzo3Department of Family and Community Medicine (DFCM), University of Toronto, Ontario, CanadaHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesYulia Green5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Serum vitamin D, magnesium and calcium on lung function and QoL in COPD: A cross-sectional studyBy Sarah Hashim Ali Hussein, Lars Peter Nielsen, Mette Konow Bogebjerg Dolberg and Ronald DahlSarah Hashim Ali Hussein1Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkLars Peter Nielsen2Department of Clinical Phamacology, Aarhus University Hospital, Aarhus, DenmarkMette Konow Bogebjerg Dolberg1Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkRonald Dahl3Allergy Centre, Odense University Hospital, Odense, Denmark
- Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trialBy Ronald Dahl, Daniel Dusser, Robert Wise, Gordon Pledger, Antonio Anzueto, Achim Mueller, Andrew Fowler and Peter CalverleyRonald Dahl1Allergy Centre, Odense University Hospital, Odense, DenmarkDaniel Dusser2Service de Pneumologie, Hopital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceRobert Wise3Medicine - Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD,Gordon Pledger4Statistics, Independent Consultant, Hamilton, TX,Antonio Anzueto5Pulmonary/Critical Care, University of Texas and South Texas Health Care System, San Antonio, TX,Achim Mueller6Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyAndrew Fowler7Medical Affairs, Boehringer Ingelheim Ltd, Bracknell, United KingdomPeter Calverley8Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
- The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM studyBy Henrik Watz, Peter Calverley, Pascal Chanez, Ronald Dahl, Marc Decramer, Bernd Disse, Helen Finnigan, Anne Kirsten, Roberto Rodriguez-Roisin, Kay Tetzlaff, Lesley Towse, Emiel Wouters and Helgo MagnussenHenrik Watz1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyPeter Calverley2Institute of Ageing and Chronic Disease, University Hospital Aintree, Liverpool, United KingdomPascal Chanez3Service de Pneumologie, Hôpital Nord, Marseille, FranceRonald Dahl4Allergy Centre, Odense University Hospital, Odense, DenmarkMarc Decramer5Department of Respiratory Diseases, University of Leuven, Leuven, BelgiumBernd Disse6Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyHelen Finnigan7Biometry and Data Management Department, Boehringer Ingelheim (UK), Berkshire, United KingdomAnne Kirsten1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyRoberto Rodriguez-Roisin8Servei de Pneumologia (ICT), Hospital Clínic-IDIBAPS-CIBERES, Barcelona, SpainKay Tetzlaff6Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany9Department of Sports Medicine, University of Tübingen, Tübingen, GermanyLesley Towse10Clinical Research Department, Boehringer Ingelheim (UK), Berkshire, United KingdomEmiel Wouters11Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, NetherlandsHelgo Magnussen1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany
- Safety of tiotropium in renally impaired patientsBy Donald Tashkin, Norbert Metzdorf, Christoph Hallmann, Michael Könen-Bergmann, Katrin Kupas and Ronald DahlDonald Tashkin1Department of Medicine, David Geffen School of Medicine UCLA, Los Angeles, CA,Norbert Metzdorf2Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyChristoph Hallmann2Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyMichael Könen-Bergmann2Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyKatrin Kupas3Clinical Operations + Biom. and Data Man., Independant Statistical Consultant, Frankfurt, GermanyRonald Dahl4Allergy Centre, Odense University Hospital, Odense, Denmark
- Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trialBy Peter Calverley, Daniel Dusser, Robert Wise, Gordon Pledger, Ronald Dahl, Achim Mueller, Jessica Montero Caballero and Antonio AnzuetoPeter Calverley1Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomDaniel Dusser2Service de Pneumologie, Hopital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceRobert Wise3Medicine - Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD,Gordon Pledger4Statistics, Independent Consultant, Houston, TX,Ronald Dahl5Allergy Centre, Odense University Hospital, Odense, DenmarkAchim Mueller6Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyJessica Montero Caballero7Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyAntonio Anzueto8Pulmonary/Critical Care, University of Texas and South Texas Health Care System, San Antonio, TX,
- Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-very severe COPD: A pooled analysisBy Ronald Dahl, Roland Buhl, Karen Mezzi, Agnes Schubert-Tennigkeit, Hungta Chen, Donald Banerji and Robert FogelRonald Dahl1Department of Dermatology, Allergy Centre, Odense University Hospital, Odense, DenmarkRoland Buhl2Pulmonary Department, Mainz University Hospital, Mainz, GermanyKaren Mezzi3Primary Care, Novartis Pharma AG, Basel, SwitzerlandAgnes Schubert-Tennigkeit3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat®By Ronald Dahl, Hendrik Schmidt, Michael Könen-Bergmann and Norbert MetzdorfRonald Dahl1Allergy Centre, Odense University Hospital, Odense, DenmarkHendrik Schmidt2Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyMichael Könen-Bergmann3Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyNorbert Metzdorf3Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
- The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM studyBy Helgo Magnussen, Pascal Chanez, Ronald Dahl, Marc Decramer, Bernd Disse, Helen Finnigan, Anne Kirsten, Roberto Rodriguez-Roisin, Kay Tetzlaff, Lesley Towse, Henrik Watz, Emiel Wouters and Peter CalverleyHelgo Magnussen1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyPascal Chanez2Service de Pneumologie, Hôpital Nord, Marseille, FranceRonald Dahl3Allergy Centre, Odense University Hospital, Odense, DenmarkMarc Decramer4Department of Respiratory Diseases, University of Leuven, Leuven, BelgiumBernd Disse5Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyHelen Finnigan6Biometry and Data Management Department, Boehringer Ingelheim (UK), Berkshire, United KingdomAnne Kirsten1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyRoberto Rodriguez-Roisin7Servei de Pneumologia (ICT), Hospital Clínic-IDIBAPS-CIBERES, Barcelona, SpainKay Tetzlaff5Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany8Department of Sports Medicine, University of Tübingen, Tübingen, GermanyLesley Towse9Clinical Research Department, Boehringer Ingelheim (UK), Berkshire, United KingdomHenrik Watz1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyEmiel Wouters10Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, NetherlandsPeter Calverley11Institute of Ageing and Chronic Disease, University Hospital Aintree, Liverpool, United Kingdom
- Detection of previously undiagnosed COPD: A role for bronchodilator reversibility testing?By Peter Kjeldgaard, Jens Dollerup, Ronald Dahl, Anders Løkke and Charlotte Suppli UlrikPeter Kjeldgaard1Pulmonary Medicine, Hvidovre Hospital, Hvidovre, DenmarkJens Dollerup2R&D, Pfizer, Ballerup, DenmarkRonald Dahl3Pulmonary Medicine, Århus Hospital, Århus, DenmarkAnders Løkke3Pulmonary Medicine, Århus Hospital, Århus, DenmarkCharlotte Suppli Ulrik1Pulmonary Medicine, Hvidovre Hospital, Hvidovre, Denmark
- 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthmaBy Roland Buhl, Kai-Michael Beeh, Wolfgang Timmer, Piet Cornelissen, Ralf Sigmund, Ashish Sharma, Michael Engel, Petra Moroni-Zentgraf and Ronald DahlRoland Buhl1Pulmonary Department, Mainz University Hospital, Mainz, GermanyKai-Michael Beeh2Pulmonary Department, Insaf Institut für Atemwegsforschung GmbH, Wiesbad, GermanyWolfgang Timmer3Clinical Pharmacology, Inamed GmbH, Gauting, GermanyPiet Cornelissen4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyRalf Sigmund5Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyAshish Sharma4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyMichael Engel4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyPetra Moroni-Zentgraf4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyRonald Dahl6Allergy Centre, Odense University Hospital, Odense, Denmark
- Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trialBy Peter Calverley, Kay Tetzlaff, Achim Mueller, Norbert Metzdorf, Bernd Disse and Ronald DahlPeter Calverley1Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomKay Tetzlaff2Clinical Research, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, GermanyAchim Mueller3Global Clinical Operations + Biom. and Data Man., Boehringer Ingelheim Pharma GmbH Co & KG, Biberach, GermanyNorbert Metzdorf2Clinical Research, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, GermanyBernd Disse2Clinical Research, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, GermanyRonald Dahl4Clinical Development + Medical Affairs, Boehringer Ingelheim Pharma GmbH Co & KG, Ingelheim am Rhein, Germany
- Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA useBy Ronald Dahl, Thomas Casale, Eugene Bleecker, Emilio Pizzichini, Michael Engel, Petra Moroni-Zentgraf, Louis Bour and Huib KerstjensRonald Dahl1Allergy Centre, Odense University Hospital, Odense, DenmarkThomas Casale2Division of Allergy and Immunology, University of South Florida, Tampa, FL United StatesEugene Bleecker3Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC United StatesEmilio Pizzichini4NUPAIVA (Asthma Research Centre), Universidade Federal de Santa Catarina, Florianópolis, BrazilMichael Engel5TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyPetra Moroni-Zentgraf5TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyLouis Bour6Biostatistics, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyHuib Kerstjens7Department of Pulmonary Medicine, University of Groningen, Groningen, Netherlands
- Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?By William W. Busse, Ronald Dahl, Christine Jenkins and Alvaro A. CruzWilliam W. Busse1University of Wisconsin School of Medicine and Public Health, Madison, WI, USARonald Dahl2Allergy Centre, Odense University Hospital, Odense, DenmarkChristine Jenkins3The George Institute for Global Health, Sydney, AustraliaAlvaro A. Cruz4ProAR – Universidade Federal da Bahia, Bahia, Brazil
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.